These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 38166148)
1. Price negotiation and pricing of anticancer drugs in China: An observational study. Zhou J; Lan T; Lu H; Pan J PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148 [TBL] [Abstract][Full Text] [Related]
2. Association of Launch Price and Clinical Value With Reimbursement Decisions for Anticancer Drugs in China. Zhou J; Lu H; Pan J Int J Health Policy Manag; 2024; 13():8150. PubMed ID: 38618837 [TBL] [Abstract][Full Text] [Related]
3. Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China. Zhang Y; Wei Y; Li H; Chen Y; Guo Y; Han S; Shi L; Guan X Pharmacoeconomics; 2022 Jul; 40(7):715-724. PubMed ID: 35764914 [TBL] [Abstract][Full Text] [Related]
4. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China. Mingge X; Jingyu W; Qi L; Zhe Z; Qing R Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066 [TBL] [Abstract][Full Text] [Related]
5. The correlation between the costs and clinical benefits of national price-negotiated anticancer drugs for specific cancers in China. Bao Y; Liu Y; Ma R; Zhang P; Li X J Glob Health; 2023 Nov; 13():04140. PubMed ID: 37934965 [TBL] [Abstract][Full Text] [Related]
6. Progress on drug pricing negotiations in China. Tang M; Song P; He J Biosci Trends; 2020 Jan; 13(6):464-468. PubMed ID: 31875587 [TBL] [Abstract][Full Text] [Related]
7. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy. Trotta F; Mayer F; Barone-Adesi F; Esposito I; Punreddy R; Da Cas R; Traversa G; Perrone F; Martini N; Gyawali B; Addis A BMJ Open; 2019 Dec; 9(12):e033728. PubMed ID: 31826897 [TBL] [Abstract][Full Text] [Related]
8. Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines? Huang C; Ung COL; Wushouer H; Bai L; Huang T; Li X; Guan X; Shi L Health Res Policy Syst; 2022 Jan; 20(1):3. PubMed ID: 34980159 [TBL] [Abstract][Full Text] [Related]
9. The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis. Luo X; Du X; Huang L; Guo Q; Tan R; Zhou Y; Li Z; Xue X; Li T; Le K; Qian F; Chow SC; Yang Y Lancet Reg Health West Pac; 2023 Mar; 32():100670. PubMed ID: 36785854 [TBL] [Abstract][Full Text] [Related]
10. From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy. Rossini EE; Galeone C; Lucchetti C; Jommi C Pharmacoecon Open; 2024 Mar; 8(2):251-261. PubMed ID: 38228997 [TBL] [Abstract][Full Text] [Related]
11. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China. Zhang Y; Wushouer H; Han S; Fu M; Guan X; Shi L; Wagner A BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34266848 [TBL] [Abstract][Full Text] [Related]
12. Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany. Lauenroth VD; Kesselheim AS; Sarpatwari A; Stern AD Health Aff (Millwood); 2020 Jul; 39(7):1185-1193. PubMed ID: 32634355 [TBL] [Abstract][Full Text] [Related]
13. Impact of medical insurance access negotiation on the utilization of innovative anticancer drugs in China: an interrupted time series analysis. Li C; Zhu J; Shan L; Zhou Y; Liu G; Zhu H; Wu Q; Cui Y; Kang Z BMC Health Serv Res; 2024 Jan; 24(1):90. PubMed ID: 38233857 [TBL] [Abstract][Full Text] [Related]
14. Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China. Luo Z; Gyawali B; Han S; Shi L; Guan X; Wagner AK Semin Oncol; 2021 Apr; 48(2):141-144. PubMed ID: 33875231 [TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966 [TBL] [Abstract][Full Text] [Related]
16. Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price. Michaeli JC; Michaeli T; Trapani D; Albers S; Dannehl D; Würstlein R; Michaeli DT Breast Cancer; 2024 Nov; 31(6):1144-1155. PubMed ID: 39320645 [TBL] [Abstract][Full Text] [Related]
17. Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology. Michaeli DT; Michaeli T Value Health; 2023 Nov; 26(11):1590-1600. PubMed ID: 37516196 [TBL] [Abstract][Full Text] [Related]
18. The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data. Yang Y; Zhang Y; Wagner AK; Li H; Shi L; Guan X J Glob Health; 2023 Aug; 13():04083. PubMed ID: 37566690 [TBL] [Abstract][Full Text] [Related]
19. Impact of competition on reimbursement decisions for cancer drugs in China: an observational study. Guan H; Shi Y; Song J; Cao M; Sun A; Liu S; Chang S; Zhao Z Lancet Reg Health West Pac; 2024 Sep; 50():101157. PubMed ID: 39156118 [TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]